TL;DR
Although HCL translated less protein than either WGE or RRL systems, it showed several advantages, notably a larger linear range and greater sensitivity to mRNA thermal stress and dsRNA impurities.
circRNA-based cancer vaccines and in vivo chimeric antigen receptor T (CAR-T) cell immunotherapies have been documented successively, but the issue of circRNA immunogenicity remains unresolved.
The versatility of the assay is demonstrated and a 4-fold reduction in 5' cap concentration for in vitro transcription results in equivalent translation in cellulo, illustrating how split luminescent tagging can be easily integrated into the mRNA therapeutic workflow, enabling monitoring of real-time mRNA-driven protei...
Messenger RNA (mRNA) vaccines are a versatile platform for rapid vaccine development; however, nucleoside modifications must be optimized to balance translational efficiency and innate immune activation. Here, we evaluated N1-ethylpseudouridine (Et1Ψ) as an alternative to the widely used N1-methylpseudouridine (m1Ψ). E...
Despite the prevalent use of mRNA vaccines, from protein replacement therapy to infectious diseases and cancer, their accessibility remains limited, particularly to low- and middle-income countries. Here, the development and in vitro characterization of a DENV-based RNA vector (DV-RNA) is described, which can overcome...
Challenges persist, including low circularization efficiency for long sequences, elevated manufacturing costs, and inadequate quality control standards, and addressing these issues through improved production workflows and delivery technologies adapted to resource-limited settings will be critical to establishing circR...
Evidence from published clinical studies and 65 registered clinical trials on mRNA-based cancer vaccines are synthesized, summarizing key molecular principles, delivery strategies, clinical translation in solid tumors, and ongoing opportunities for future therapeutic development are summarized.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
